annb0t
Top 20
Haemonetics Corporation HAE delivered adjusted earnings per share (EPS) of 90 cents for the fourth quarter of fiscal 2024, up 16.9% year over year. The bottom line surpassed the Zacks Consensus Estimate by 2.3%.
On a GAAP basis, EPS was 40 cents, down 29.8% from the prior-year quarterâs levels.
For the full year, adjusted earnings were $3.96 per share, up 30.7% from the year-ago periodâs figure. It beats the Zacks Consensus Estimate by 03%.
Total Revenues
Revenues increased 12.8% t...
>>> Read more: Haemonetics (HAE) Q4 Earnings Top Estimates, Margins Expand
On a GAAP basis, EPS was 40 cents, down 29.8% from the prior-year quarterâs levels.
For the full year, adjusted earnings were $3.96 per share, up 30.7% from the year-ago periodâs figure. It beats the Zacks Consensus Estimate by 03%.
Total Revenues
Revenues increased 12.8% t...
>>> Read more: Haemonetics (HAE) Q4 Earnings Top Estimates, Margins Expand
